Invictus RG purchased a new stake in Orthofix International N.V. (NASDAQ:OFIX) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 7,234 shares of the medical device company’s stock, valued at approximately $342,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Pinebridge Investments L.P. raised its position in Orthofix International by 2.3% in the 2nd quarter. Pinebridge Investments L.P. now owns 2,378 shares of the medical device company’s stock valued at $111,000 after buying an additional 53 shares during the last quarter. State of Alaska Department of Revenue grew its stake in Orthofix International by 79.3% in the 2nd quarter. State of Alaska Department of Revenue now owns 3,551 shares of the medical device company’s stock valued at $165,000 after purchasing an additional 1,571 shares during the period. Municipal Employees Retirement System of Michigan bought a new position in Orthofix International in the 2nd quarter valued at $196,000. Los Angeles Capital Management & Equity Research Inc. bought a new position in Orthofix International in the 3rd quarter valued at $315,000. Finally, BNP Paribas Arbitrage SA grew its stake in Orthofix International by 64.3% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 7,651 shares of the medical device company’s stock valued at $356,000 after purchasing an additional 2,995 shares during the period. 94.61% of the stock is owned by institutional investors and hedge funds.

In other Orthofix International news, CEO Brad Mason sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, November 28th. The stock was sold at an average price of $53.48, for a total value of $267,400.00. Following the completion of the transaction, the chief executive officer now owns 183,053 shares in the company, valued at approximately $9,789,674.44. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Luke T. Faulstick sold 4,800 shares of the firm’s stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $51.22, for a total value of $245,856.00. Following the completion of the transaction, the director now owns 7,729 shares of the company’s stock, valued at approximately $395,879.38. The disclosure for this sale can be found here. Insiders have sold a total of 24,109 shares of company stock valued at $1,220,840 in the last quarter. 5.60% of the stock is owned by corporate insiders.

Orthofix International N.V. (NASDAQ:OFIX) opened at $52.72 on Wednesday. The firm has a market capitalization of $962.78, a price-to-earnings ratio of 34.52, a PEG ratio of 2.62 and a beta of 0.14. Orthofix International N.V. has a 12 month low of $32.51 and a 12 month high of $54.73.

Orthofix International (NASDAQ:OFIX) last posted its quarterly earnings results on Monday, October 30th. The medical device company reported $0.42 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.01. The company had revenue of $105.30 million during the quarter, compared to the consensus estimate of $100.67 million. Orthofix International had a return on equity of 10.26% and a net margin of 0.33%. The firm’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.36 EPS. equities analysts expect that Orthofix International N.V. will post 1.61 earnings per share for the current year.

OFIX has been the subject of a number of recent analyst reports. Zacks Investment Research downgraded Orthofix International from a “buy” rating to a “hold” rating in a research note on Wednesday, November 8th. BTIG Research set a $56.00 price objective on Orthofix International and gave the company a “buy” rating in a research note on Monday, October 30th. TheStreet downgraded Orthofix International from a “b” rating to a “c+” rating in a research note on Tuesday, October 31st. BidaskClub upgraded Orthofix International from a “hold” rating to a “buy” rating in a research note on Thursday, August 17th. Finally, Jefferies Group restated a “buy” rating and issued a $55.00 price objective (up previously from $50.00) on shares of Orthofix International in a research note on Thursday, August 10th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $54.42.

WARNING: This report was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://theolympiareport.com/2017/12/06/invictus-rg-purchases-new-stake-in-orthofix-international-n-v-ofix.html.

About Orthofix International

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Want to see what other hedge funds are holding OFIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Orthofix International N.V. (NASDAQ:OFIX).

Institutional Ownership by Quarter for Orthofix International (NASDAQ:OFIX)

Receive News & Ratings for Orthofix International N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.